Velpanat Tablet

Velpanat Tablet is a highly advanced direct-acting antiviral (DAA) medication used for the treatment of chronic Hepatitis C Virus (HCV) infection. It is a fixed-dose combination of Sofosbuvir 400 mg and Velpatasvir 100 mg, two clinically proven antiviral agents that work together to eliminate the Hepatitis C virus from the body. This once-daily oral therapy has become one of the most trusted and widely prescribed treatment options due to its exceptional cure rates, pan-genotypic activity, convenient dosing schedule, and excellent safety profile. Velpanat offers an effective, interferon-free solution that helps patients achieve long-term viral clearance while protecting liver function and improving overall health.

Velpanat combines the antiviral power of Sofosbuvir, an NS5B RNA polymerase inhibitor, with Velpatasvir, an NS5A inhibitor. Sofosbuvir prevents the virus from reproducing by blocking the enzyme responsible for viral RNA replication, while Velpatasvir inhibits the NS5A protein, which is essential for viral replication and the formation of new virus particles. By attacking the Hepatitis C virus through two different mechanisms, this combination effectively suppresses viral activity, reduces the possibility of resistance, and promotes complete viral eradication.

One of the most significant advantages of Velpanat Tablet is its pan-genotypic effectiveness, making it suitable for treating all six major Hepatitis C genotypes (Genotypes 1, 2, 3, 4, 5, and 6). This broad-spectrum antiviral activity allows physicians to prescribe Velpanat without the need for complex genotype-specific treatment strategies in many cases. It is commonly recommended for adults with chronic Hepatitis C, including treatment-naïve patients, previously treated patients, and many individuals with compensated liver cirrhosis. Depending on the patient's medical condition and physician's recommendation, treatment generally lasts 12 weeks, although certain patients with advanced liver disease or additional clinical considerations may require an extended treatment duration.

Clinical studies have demonstrated sustained virologic response (SVR) rates exceeding 95%, indicating successful elimination of the virus after completion of therapy in the majority of patients. Achieving SVR significantly reduces the risk of progressive liver damage, fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Early diagnosis and prompt treatment with Velpanat can preserve liver health, improve life expectancy, and enhance the overall quality of life for individuals living with chronic Hepatitis C.

Velpanat Tablet is administered orally as one tablet once daily, with or without food. Patients are encouraged to take the medicine at the same time every day to maintain stable blood concentrations and maximize treatment effectiveness. Completing the full course of therapy without missing doses is essential for achieving optimal antiviral results and preventing viral relapse. Patients should never discontinue treatment without consulting their healthcare provider.

Compared with older interferon-based treatment regimens, Velpanat offers a much better safety profile and is generally well tolerated by most patients. Common side effects are usually mild and may include headache, fatigue, nausea, dizziness, insomnia, diarrhea, or mild weakness. These symptoms often resolve naturally as treatment continues. Serious side effects are uncommon when the medication is used according to medical advice. Healthcare professionals may recommend periodic blood tests and liver function monitoring throughout treatment to ensure the medication is working effectively and safely.

Before beginning therapy, patients should inform their healthcare provider about any history of liver disease, kidney impairment, hepatitis B infection, HIV infection, pregnancy, breastfeeding, or other existing medical conditions. They should also disclose all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements they are currently taking, as certain medications may interact with Sofosbuvir or Velpatasvir. Alcohol consumption should be avoided during treatment because it may further damage the liver and reduce the overall benefits of antiviral therapy.